Search Results

Featured Topics

Toggle

Showing 20 of 20 results

Biopharmaceuticals

  1. Home
  2. Product Focus
Teva Pharmaceuticals is investing in original biologic medicines and in biosimilars focusing central nervous system respiratory conditions and in oncology

John Bottrell
John Bottrell is a respiratory therapist who s lived with asthma for most of his life

Teva Reinforces Leadership Position in Respiratory with Acquisition of Gecko Health Innovations

Teva to Present New Respiratory Data at 2015 Annual International Meeting of the American Thoracic Society

Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy Asthma and Immunology

Teva to Present New Respiratory Data at the 2015 Annual Scientific Meeting of the American College of Allergy Asthma and Immunology

Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform

Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference

Teva to Present New Respiratory Data at the 2016 Academy of Allergy Asthma and Immunology Annual Meeting

Digital Health The new standard

  1. Home
  2. News and Media
  3. Feature Stories
Asthma and COPD affect over 500 million people worldwide Learn more from Sven Dethlefs EVP Global Marketing Portfolio and International Markets as he discusses how Teva is trying to address respiratory diseases through digital health solutions

Teva Highlights Growing Respiratory Portfolio at the 2016 American College of Allergy Asthma Immunology Annual Scientific Meeting

Teva s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U S Health System

A brief history of biopharmaceuticals

  1. Home
  2. Product Focus
  3. Biopharmaceuticals

The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva s Reslizumab for the Treatment of Moderate to Severe Asthma in Patients with Elevated Blood Eosinophils

Biopharmaceuticals at Teva

  1. Home
  2. Product Focus
  3. Biopharmaceuticals
Discover what biopharmaceuticals are and how Teva Pharmaceuticals does invest in this domain

Out of the Limelight Supporting Millions of Non COVID Patients in Their Journey Back to Healthcare Post COVID 19 Pandemic

  1. Home
  2. News and Media
  3. Feature Stories
How Teva is supporting patients to return to healthcare systems to help avert a new healthcare crisis in non COVID diseases

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir Digihaler albuterol sulfate Inhalation Powder at the European Respiratory Society ERS International Congress 2022

Company Info Teva in Facts and Figures

  1. Home
  2. Our Company
Discover the facts and figures about Teva Pharmaceuticals and see how we achieve our vision to be a global leader in innovative medicines and generics

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual Action Asthma Rescue Inhaler ICS SABA TEV 248 Respiratory Program Teva and Abingworth Enter Strategic Development Funding Agreement